Download A4Medicine Mobile App
Empower Your RCGP AKT Journey: Master the MCQs with Us! đ
Immunocompromised patients face a markedly elevated risk of pulmonary infections due to their impaired immune responses. This diverse groupâwhich includes individuals living with HIV/AIDS, solid organ and stem cell transplant recipients, patients undergoing cancer chemotherapy, and those receiving biologic or other immunosuppressive therapiesârequires special consideration in clinical practice. In the realm of primary care, particularly within the UK, a proactive and individualized approach is critical. Clinicians must prioritize strategies that encompass prevention measures such as timely immunisations and chemoprophylaxis, diligent monitoring for early signs of respiratory distress, and prompt referral to specialist care when necessary.
Standard treatment protocols for community-acquired pneumonia often fall short for immunosuppressed individuals, whose clinical presentations can be atypical and whose infections tend to involve a broader array of pathogens. These pathogens include not only conventional bacterial agents but also a variety of viral and fungal organisms. For instance, infections by pathogens such as Cryptococcus neoformans, Aspergillus species, and Nocardia spp. can cause severe, life-threatening pulmonary complications, especially among patients with advanced immunodeficiency or those undergoing intensive chemotherapy.
Recent epidemiological data illustrate the substantial burden of pulmonary infections in this vulnerable population. In the United States alone, an estimated 3 million individuals live with conditions that compromise immune function, contributing to infection rates ranging from 30% to 70% among certain high-risk groups. The clinical course of these infections is often severe, with acute cases frequently leading to prolonged hospital stays and significant healthcare costs, while chronic and recurrent respiratory complications further exacerbate patient morbidity and mortality.
Moreover, the evolving landscape of infectious diseasesâmarked by the emergence of novel respiratory pathogens and the resurgence of re-emerging viruses like human metapneumovirus and adenovirusâcomplicates the management landscape even further. These pathogens not only challenge established diagnostic and therapeutic algorithms but also underscore the need for an enhanced surveillance system and tailored management protocols that integrate specialist insights into primary care settings.
Patient Populations and Risk Factors
People with HIV/AIDS, especially those with advanced disease (CD4 count <200 cells/ÎźL), have severely compromised cell-mediated immunity, making them vulnerable to opportunistic infections such as Pneumocystis jirovecii pneumonia (PJP), tuberculosis, and recurrent bacterial respiratory infections. Effective antiretroviral therapy (ART) plays a crucial role in reducing these risks through immune reconstitution. Primary care must ensure that HIV patients are consistently engaged with specialist services and adhere to ART. When CD4 counts are low, additional precautions including prophylaxis and appropriately tailored immunisation plans are essential, noting that live vaccines (such as varicella and MMR) are contraindicated in patients with significant immunosuppression.
| Patient Population | Key Characteristics & Risk Factors | Prevention & Management Considerations |
|---|---|---|
| People with HIV/AIDS |
Advanced/untreated HIV (CD4 count <200 cells/ÎźL â) severely compromises cell-mediated immunity. Prone to opportunistic infections (e.g., Pneumocystis jirovecii pneumonia, Mycobacterium tuberculosis) and recurrent bacterial respiratory infections. |
Effective antiretroviral therapy (ART) to restore immune function. Ensure specialist engagement and ART adherence. Additional precautions (prophylaxis, tailored immunisations); avoid live vaccines (e.g., varicella, MMR) when CD4 counts are low. |
| Transplant Recipients |
Includes solid organ and hematopoietic stem cell transplant patients. Undergo prolonged immunosuppression; highest risk in the first 3â6 months post-transplant with ongoing vulnerability. Susceptible to opportunistic pneumonias (e.g., PJP, CMV pneumonitis, invasive fungal infections like Aspergillus). |
Strict prophylaxis protocols (e.g., PJP prophylaxis for 6â12 months, antiviral prophylaxis for CMV). Coordination with transplant centers for monitoring immunosuppressive medications and drug interactions. Avoid live vaccines post-transplant; use inactivated alternatives (e.g., inactivated flu vaccine). |
| Patients on Cancer Treatment |
Often undergoing chemotherapy, especially for hematological malignancies. Experience neutropenia (â) and mucosal damage, heightening risk of severe bacterial pneumonia (including gram-negatives) and fungal infections (e.g., invasive aspergillosis). Increased risk of PJP in certain regimens. |
Immediate hospital referral for signs of neutropenic sepsis (fever, respiratory symptoms) as per UK guidelines. Prophylaxis with co-trimoxazole where indicated. Maintain up-to-date immunisations (e.g., annual flu vaccine) as counts recover between cycles. Educate patients on urgent care seeking during neutropenic episodes. |
| Patients on Biologic/Other Immunosuppressive Therapies |
Involves patients on high-dose corticosteroids, DMARDs (e.g., methotrexate), and biologics (e.g., anti-TNF, rituximab). Immunosuppression varies by agent (e.g., anti-TNF increases TB reactivation risk; rituximab predisposes to encapsulated bacterial infections). Typically managed with specialist co-management. |
Mandatory screening for latent TB, hepatitis B/C prior to therapy. Initiate appropriate prophylaxis (e.g., antivirals for HBV reactivation). Keep immunisations up-to-date (pneumococcal, influenza, varicellaâif given pre-therapy). Monitor for infection signs; liaise with specialists for any new respiratory issues. Consider Pneumocystis pneumonia (PJP) prophylaxis for patients on prolonged high-dose steroids. |
Causes
Infectious Causes: Predominate in immunocompromised patients, including bacterial, mycobacterial, viral, fungal, and parasitic infections.
Non-Infectious Causes: Include drug-induced lung injury, immune-mediated lung disorders (e.g., IPS, DAH, engraftment syndrome), post-transplant complications such as bronchiolitis obliterans and PTLD, as well as other conditions like pulmonary edema, embolism, and idiopathic interstitial lung diseases.
| Category | Details |
|---|---|
| I. Infectious Causes | |
| Bacterial Infections |
Typical Bacteria:
|
| Mycobacterial Infections |
Mycobacterium tuberculosis (TB): Reactivation is common, especially in HIV-positive patients and those on anti-TNF therapies. Non-Tuberculous Mycobacteria (NTM): Such as Mycobacterium avium-intracellulare complex, often seen in patients with advanced HIV or structural lung disease. |
| Viral Infections |
Common Respiratory Viruses:
|
| Fungal Infections |
|
| Parasitic Infections | Though rare, in certain endemic areas, parasites (e.g., Strongyloides stercoralis hyperinfection) may involve the lungs. |
| II. Non-Infectious Causes | |
| Drug-Induced Lung Injury |
Chemotherapy-Related Toxicity: e.g., bleomycin or methotrexate-induced pneumonitis and fibrosis. Biologic Agents: Immune checkpoint inhibitors or anti-TNF therapies may result in interstitial lung disease. Radiation Pneumonitis: May occur after radiotherapy and mimic infectious pneumonia. |
| Immune-Mediated/Inflammatory Conditions |
|
| Malignancy-Related Conditions |
|
| Other Non-Infectious Pulmonary Pathologies |
|
Approach to Managing an Immunocompromised Patient with Suspected Pulmonary Infection
Initial Assessment
History Taking:
Obtain a comprehensive medical history.
Identify the patientâs immunocompromised status (e.g., organ transplant, HIV, recent chemotherapy).
Symptom Review:
Document key symptoms including cough, fever, dyspnea, chest pain, and sputum production.
Include relevant details such as travel history, exposure risks, and underlying conditions.
Medication Review:
Assess current medications, with special attention to any immunosuppressive therapies that may affect both presentation and management.
Physical Examination
Conduct a thorough respiratory exam with focus on:
Auscultation for abnormal lung sounds (e.g., crackles, wheezing).
Assess for systemic signs of infection:
Fever, tachycardia, and changes in respiratory rate or effort.
Diagnostic Workup
Laboratory Tests:
Complete blood count (CBC) to assess white blood cell (WBC) counts.
Blood cultures if sepsis or systemic infection is suspected.
Imaging:
Obtain a chest X-ray (CXR) to look for infiltrates, effusions, or cavities.
If findings are inconclusive or abnormal, consider a chest CT scan for a detailed evaluation.
Microbiological Testing
Sputum Culture:
Collect samples for microbiological analysis and antibiotic sensitivity testing.
Bronchoalveolar Lavage (BAL):
Consider BAL if initial tests remain inconclusive or if significant pulmonary involvement is suspected; this method helps in identifying pathogens, including fungi and atypical bacteria.
PCR Testing:
Utilize PCR for suspected viral infections (e.g., cytomegalovirus, influenza), especially in critically ill immunocompromised patients.
Acute Onset: High suspicion for typical bacterial pathogens. Rapid deterioration often means immediate empirical treatment is needed.
Subacute Onset: Raises concern for opportunistic infections (e.g., PCP, Nocardia, or certain viruses) or early invasive fungal infections. A thorough history, including prophylactic regimens and recent changes in immunosuppression, is essential.
Chronic Onset: Suggests infections with slow-growing pathogens (e.g., NTM, CPA) or non-infectious causes like bronchiolitis obliterans or PTLD. This scenario often necessitates more extensive investigation, including imaging, laboratory testing, and sometimes tissue biopsy.
| Presentation | Clinical Features | Likely Causes | Clinical Tips |
|---|---|---|---|
| Acute (Hours to Days) |
Symptoms: Rapid onset high fever, chills, marked dyspnea, pleuritic chest pain, and possible hemoptysis; rapid deterioration with severe hypoxia. Signs: Tachypnea, tachycardia, hypotension, hypoxemia; sometimes deceptively mild if immune response is blunted. |
Infectious:
Bacterial: Streptococcus pneumoniae, Staphylococcus aureus; Gram-negative bacilli (e.g., Pseudomonas aeruginosa, Klebsiella pneumoniae). Viral: Influenza, SARS-CoV-2. Fungal: Invasive aspergillosis, mucormycosis, and breakthrough Pneumocystis jirovecii pneumonia (PCP). Non-Infectious: ARDS, diffuse alveolar hemorrhage (DAH), drug-induced lung injury, pulmonary embolism. |
Immediate workup with rapid imaging (CXR/CT), blood cultures, and urinary antigen tests. Initiate broad-spectrum antibiotics (following IDSA guidelines in neutropenic patients) and escalate care promptly. |
| Subacute (Days to Weeks) |
Symptoms: Gradual onset of a dry or minimally productive cough, low-grade fever, progressive dyspnea, and malaise. Signs: Diffuse or patchy infiltrates on imaging; clinical exam may appear less dramatic than radiologic findings. |
Infectious:
Fungal/Atypical: Pneumocystis jirovecii (PCP), Nocardia, invasive aspergillosis, Cryptococcus. Viral: CMV pneumonitis (especially in transplant recipients), adenovirus. Non-Infectious: Idiopathic pneumonia syndrome (IPS), engraftment syndrome, organizing pneumonia, drug-induced pneumonitis. |
Employ high-resolution CT imaging and targeted laboratory tests (e.g., PCR, serum/BAL β-D-glucan, galactomannan) to aid differentiation between infectious and non-infectious causes. |
| Chronic (Weeks to Months) |
Symptoms: Persistent cough (productive or dry), progressive exertional dyspnea, weight loss, and chronic fatigue; fever may be absent or low-grade. Signs: Persistent radiologic infiltrates, cavitary or nodular lesions, features of fibrosis; pulmonary function tests may reveal restrictive/obstructive patterns. |
Infectious:
Mycobacterial: Non-tuberculous mycobacteria (NTM), tuberculosis (TB). Fungal: Chronic pulmonary aspergillosis, endemic fungi (e.g., Histoplasma, Coccidioides). Non-Infectious: Bronchiolitis obliterans, post-transplant lymphoproliferative disorder (PTLD), chronic graft-versus-host disease (GVHD), drug-induced fibrosis, other mimics (e.g., sarcoidosis, radiation pneumonitis). |
Use serial imaging and pulmonary function tests (PFTs) for monitoring. Consider tissue biopsy when necessary and TB screening (e.g., IGRA) in high-risk patients. |
Immediate empiricial treatment
Empirical treatment for immunocompromised patients presenting with suspected pulmonary infection should be initiated promptly. Treatment is typically started based on the most common pathogens affecting these patients, with broad-spectrum antibiotics covering typical pathogens such as Streptococcus pneumoniae, Staphylococcus aureus, and Gram-negative organisms like Pseudomonas.
| Aspect | Recommendation / Intervention | Examples / Notes |
|---|---|---|
| Initiate Therapy Promptly | Begin treatment based on common pathogens in immunocompromised patients. | Early administration is critical to prevent rapid deterioration. |
| Broad-Spectrum Antibiotics | Start agents covering typical pathogens (e.g., Streptococcus pneumoniae, Staphylococcus aureus, Gram-negative organisms like Pseudomonas). |
|
| Antifungal Therapy | Initiate therapy if fungal infection is suspected. |
|
| Management of Co-infections | Ensure empiric therapy is broad enough to cover simultaneous bacterial and viral infections. | Empiric regimens should cover pathogens such as influenza and SARS-CoV-2 until PCR and culture data refine the diagnosis. |
| Guideline-Based Recommendations | Follow IDSA/ATS guidelines. |
|
| Antibiotic Stewardship | Avoid unnecessary broad-spectrum use in stable patients without clear bacterial signs. | In immunocompromised patients, however, early treatment is warranted due to the risk of rapid deterioration. |
| Monitoring and Follow-Up | Closely monitor vital signs, oxygenation, and symptom progression. | Adjust treatment based on laboratory results, imaging, and clinical reassessment. Document therapy and immunosuppressive regimen details. |
| Referral Considerations | Arrange urgent hospital transfer for high-risk patients. |
|
Yes, immediate antibiotic treatment is indicated in primary care if:
The patient exhibits high-risk features (e.g., hypoxia, neutropenia, or severe systemic signs).
There is concern for life-threatening infections (bacterial, fungal, or co-infections) especially when hospital transfer is delayed.
No, defer antibiotics if:
The patient is stable, with mild symptoms where there is confidence in rapid specialist evaluation and diagnostic testing.
A non-infectious cause is highly suspected, and immediate antibiotic use might obscure the diagnosis.
Bottom Line:
Given the potential for rapid deterioration in immunocompromised patients, primary care clinicians should lean toward early empiric antibioticâand when indicated, antifungalâtherapy while expediting hospital referral. This strategy minimizes delays in treatment for life-threatening infections while allowing subsequent tailoring of therapy based on culture results and additional diagnostics.
| Category | Recommendation / Intervention | Comments / Considerations |
|---|---|---|
| General Principles |
|
Emphasizes high vigilance in immunocompromised patients; aligns with UK NICE and Public Health England guidelines. |
| Suspected Bacterial Pneumonia |
|
Appropriate for CAP in patients with risk factors; note that neutropenic patients generally require urgent hospital referral for IV therapy. |
| Suspected Pneumocystis jirovecii Pneumonia (PCP) |
|
Dosing should be tailored to weight/renal function; check if patient is already on prophylaxis indicating possible breakthrough infection. |
| Suspected Atypical/Viral |
|
Suitable for mild-to-moderate atypical pneumonia; helps cover Mycoplasma, Chlamydia, Legionella. |
| Key Considerations |
|
Reflects UK guidelines; underscores the importance of tailored therapy based on the immune defect. |
| Antibiotic Stewardship | Avoid unnecessary broad-spectrum agents (e.g., meropenem, vancomycin) in primary care. | Document rationale for antibiotic choice and use them as a temporary âbridgeâ until definitive management. |
| Bottom Line |
|
Primary care antibiotics are provisional until specialist intervention confirms the diagnosis and tailors management. |
Multifactorial difficulties in diagnosing and managing these complex cases.
Managing immunocompromised patients with pulmonary disease in primary care is fraught with challenges, particularly because 30% or more may have multiple overlapping pathologies (e.g., dual infections, combined infectious/non-infectious processes, or complications like pleural effusion). These complexities complicate diagnosis, treatment, and follow-up. Below is a detailed breakdown of the challenges:
Challenge:
Overlap of Symptoms:
Coexisting conditions such as a bacterial pneumonia with a superimposed fungal infection or a drug-induced lung injury with viral reactivation can all produce similar clinical features (e.g., fever, cough, hypoxia).
Example:
A patient with advanced HIV (CD4 count <100/mmÂł) might simultaneously develop Pneumocystis jirovecii pneumonia (PCP) and tuberculosis (TB). Both conditions often manifest with a subacute onset of dyspnea and diffuse infiltrates, making it difficult to tease apart the individual contributions of each process.
Implications:
Delays in recognizing one of the underlying pathologies can lead to undertreatment and subsequent clinical deterioration.
Basic investigations like a chest X-ray or CBC, while useful, may miss subtle distinguishing features (for example, cavitary lesions suggestive of TB versus ground-glass opacities typical of PCP).
Challenge:
Secondary Infections and Complications:
It is common for an immunocompromised patient to develop secondary infections (for instance, bacterial sepsis following a viral pneumonia) or non-infectious complications (e.g., pleural effusions from hypoalbuminemia, drug toxicity, or even ARDS).
Example:
A chemotherapy patient with neutropenia might first develop Pseudomonas pneumonia and then go on to develop Aspergillus tracheobronchitis. Concurrently, this patient may also develop pleural effusions related to fluid overload or underlying heart failure.
Implications:
Treatments aimed at one infection (e.g., broad-spectrum antibiotics for bacteria) may inadvertently promote overgrowth of other pathogens (e.g., fungi like Candida).
Non-infectious etiologies such as pleural effusions can be misattributed to infectious causes if not properly investigated.
Challenge:
Resource Constraints in Primary Care:
Primary care settings may lack rapid access to high-resolution CT scans, bronchoscopy with bronchoalveolar lavage (BAL), or advanced serologic/molecular tests (such as β-D-glucan, galactomannan, or PCR assays) that are needed for definitive diagnoses.
Implications:
Clinicians are often compelled to initiate empiric therapy without microbiologic confirmation, which may lead to inappropriate or suboptimal treatment (for instance, missing diagnoses like non-tuberculous mycobacteria or Cryptococcus).
Delayed referrals for advanced diagnostics prolong diagnostic uncertainty and risk clinical deterioration.
Challenge:
Polypharmacy and Drug-Drug Interactions:
Many immunocompromised patients are already on complex treatment regimens (e.g., immunosuppressants, prophylactic antibiotics). Adding empiric therapyâoften broad-spectrum antibiotics and, when indicated, antifungalsâelevates the risk of adverse drug interactions and toxicity.
Example:
A transplant patient on tacrolimus might develop CMV pneumonitis requiring valganciclovir; however, valganciclovir can further suppress bone marrow function, complicating the medication regimen.
Implications:
Specialists must often be involved to adjust immunosuppression and manage potential toxicity.
Adherence can be adversely affected, which may lead to relapse or treatment failures.
Challenge:
Sudden Decompensation:
Immunocompromised patients may decompensate rapidly due to co-infections (e.g., bacterial sepsis superimposed on a viral pneumonia) or progression to severe conditions like ARDS.
Implications:
Primary care settings may not be equipped with the necessary resources (e.g., oxygen, IV fluids, close monitoring) to manage sudden decompensation. This heightens the urgency of rapid hospital referral in patients with high-risk features.
Challenge:
Fragmented Communication:
Effective management often demands the collaboration of multiple specialists (infectious disease, pulmonology, oncology/transplant teams). In primary care, coordination may be slowed by limited communication channels or the need for formal referrals, which can delay critical interventions.
Implications:
Delays in procedures such as bronchoscopy or in obtaining specialist consultation can result in prolonged diagnostic uncertainty and worsened outcomes.
Primary care clinicians might have limited authority or logistical capacity to expedite these referrals.
Challenge:
Persistent Immunosuppression and Relapse:
Approximately 30% of patients experience relapse or persistent infections due to factors such as inadequate initial treatment (e.g., undiagnosed drug-resistant TB) or continued immunosuppression (e.g., prolonged use of corticosteroids).
Example:
A patient with chronic pulmonary aspergillosis may develop recurrent bacterial pneumonia due to underlying bronchiectasis, necessitating frequent follow-up.
Implications:
Regular follow-up, frequent reassessment, and repeated imaging or laboratory tests are necessary.
Logistical challenges in primary care, such as resource limitations and patient access issues, can impede the required close surveillance.
From IDSA/ATS Recommendations:
Co-infection Suspicion:
In high-risk neutropenic patients, empirical therapy may need to cover both bacterial and fungal pathogens.
Pleural Effusion Evaluation:
Thoracentesis for fluid analysis (including cell count, cultures, and cytology) is critical, even if it requires specialist referral.
Risk Stratification:
For patients with high-risk features (e.g., neutropenia, hypoxia), initiating immediate empiric therapy is advised while arranging prompt transfer to higher care.
Primary Care Strategies:
High Index of Suspicion:
Assume that multiple pathologies could be driving a patientâs deterioration in the presence of overlapping symptoms.
Early Referral:
Advocate for urgent imaging (such as high-resolution CT) or invasive diagnostics like bronchoscopy in unstable patients.
Preventive Measures:
Ensure that prophylaxis (e.g., TMP-SMX for PCP, appropriate antivirals for CMV) is current and that patients are educated regarding the recognition of red flags (e.g., new hemoptysis, marked dyspnea).
Patient Education:
Teach patients (and caregivers) to recognize signs that warrant immediate re-evaluationâespecially given that subtle changes can quickly lead to decompensation in this vulnerable group.
Managing pulmonary disease in immunocompromised patients in primary care is inherently challenging due to:
Diagnostic ambiguity from overlapping infectious and non-infectious etiologies.
Limited on-site diagnostic resources.
Complex, high-risk treatment regimens with potential for rapid deterioration.
The need for coordinated multidisciplinary care.
In these contexts, primary care providers should maintain a high index of suspicion, opt for prompt empirical treatments when high-risk features are present, and seek urgent specialist involvement when diagnostic uncertainty exists or if the patientâs condition worsens.
AST Guidelines on Post-Transplant Infections (2020)
Aslam, S., et al. "Guidelines for the Prevention and Management of Infectious Complications of Solid Organ Transplantation." American Journal of Transplantation, 2020.
Azoulay, Ă., Russell, L., Louw, A., Metaxa, V., Bauer, P., PĂłvoa, P., ⌠& Mirouse, A. (2020)
Diagnosis of severe respiratory infections in immunocompromised patients. Intensive Care Medicine, 46(2), 298â314. https://doi.org/10.1007/s00134-019-05906-5
BHIVA Guidelines
For managing opportunistic infections such as Pneumocystis jirovecii pneumonia (PCP) in HIV-positive patients.
British National Formulary (BNF)
Joint Formulary Committee. "BNF 85: March 2023." NICE, 2023.
British Thoracic Society (BTS) Guidelines for Pneumonia (2019)
British Thoracic Society. "BTS Guidelines for the Management of Community-Acquired Pneumonia in Adults." Thorax, 2019.
Donnelly, J. P., et al. (2020)
Revision and Update of the Consensus Definitions of Invasive Fungal Disease from the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium. Clinical Infectious Diseases, 2020.
Freifeld, A. G., et al. (2011)
Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic Patients with Cancer. Clinical Infectious Diseases, 2011.
(IDSA Guidelines for the Management of Neutropenic Fever)
Grover, S., Grover, H., Antil, N., Patra, S., Sen, M., & Nair, D. (2022)
Imaging approach to pulmonary infections in the immunocompromised patient. Indian Journal of Radiology and Imaging, 32(01), 081â112. https://doi.org/10.1055/s-0042-1743418
IDSA/ATS Guidelines for Community-Acquired Pneumonia (2019)
Metlay, J. P., et al. "Diagnosis and Treatment of Adults with Community-Acquired Pneumonia." American Journal of Respiratory and Critical Care Medicine, 2019.
IDSA Guidelines for HIV Opportunistic Infections (2019)
Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. "Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV." National Institutes of Health, 2019.
NICE Clinical Knowledge Summaries (CKS): Pneumonia and Antibiotic Prescribing (2023)
National Institute for Health and Care Excellence. "Pneumonia (Community-Acquired): Antimicrobial Prescribing." NICE, 2023.
NICE Guidelines
For community-acquired pneumonia and neutropenic sepsis management in the UK â emphasizing prompt referral and appropriate empiric treatment in highârisk groups.
NICE Guideline NG151: Neutropenic Sepsis (2020)
National Institute for Health and Care Excellence. "Neutropenic Sepsis: Prevention and Management in People with Cancer." NICE, 2020.
LatgĂŠ, J. and Chamilos, G. (2019)
Aspergillus fumigatus and aspergillosis in 2019. Clinical Microbiology Reviews, 33(1). https://doi.org/10.1128/cmr.00140-18
Maziarz, E. and Perfect, J. (2016)
Cryptococcosis. Infectious Disease Clinics of North America, 30(1), 179â206. https://doi.org/10.1016/j.idc.2015.10.006
RamĂrez, J., Musher, D., Evans, S., Cruz, C., Crothers, K., Hage, C., ⌠& Wunderink, R. (2020)
Treatment of community-acquired pneumonia in immunocompromised adults. Chest Journal, 158(5), 1896â1911. https://doi.org/10.1016/j.chest.2020.05.598
Y, L., Wu, W., Xiao, Y., Zou, H., Hao, S., & Jiang, Y. (2024)
Application of metagenomic next-generation sequencing and targeted metagenomic next-generation sequencing in diagnosing pulmonary infections in immunocompetent and immunocompromised patients. Frontiers in Cellular and Infection Microbiology, 14. https://doi.org/10.3389/fcimb.2024.1439472
Zhao, Z., Song, J., Yang, C., Yang, L., Chen, J., Li, X., ⌠& Feng, J. (2021)
Prevalence of fungal and bacterial co-infection in pulmonary fungal infections: a metagenomic next generation sequencing-based study. Frontiers in Cellular and Infection Microbiology, 11. https://doi.org/10.3389/fcimb.2021.749905
